Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update

American Heart Journal

Volumn 154, Issue 3, 2007, Pages 554-560

  Nichols, Gregory A ^a   Nag, Soma ^b   Chan, Wiley ^c  

^a KAISER PERMANENTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Northwest Permanente   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEALTH EDUCATION; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; UNITED STATES;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE;

EID: 34548046494     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.04.037     Document Type: Article

References (16)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 23-33
2. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 360 (2002) 1623-1630
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
4. Sever P.S., Poulter N.R., Dahlof B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
5. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
6. Grundy S.M., Cleeman J.I., Bairey-Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
7. Pearson T.A., Laurora I., Chu H., et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
8. Yan A.T., Yan R.T., Tan M., et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 119 (2006) 676-683
9. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
10. Anderson K.M., Odell P.M., Wilson P.W.F., et al. Cardiovascular disease risk profiles. Am Heart J 121 (1990) 293-298
11. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
12. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) Study. Diabetes Care 29 (2006) 1220-1226
13. Hayward R.A., Hofer T.P., and Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 145 (2006) 520-530
14. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
15. Massing M.W., Sueta C.A., Chowdhury M., et al. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 87 (2001) 646-649
16. Afonso N.W., Nassif G., Aranha A.N.F., et al. Low-density lipoprotein cholesterol goal attainment among high risk patients: does a combined intervention targeting patients and providers work?. Am J Manag Care 12 (2006) 589-594